Biotechnology

CEL-SCI

CEL-SCI released FY2026 Q2 earnings on May 15 (EST), actual revenue USD 0, actual EPS USD -0.6716

CEL-SCI released FY2026 Q1 earnings on February 17 (EST), actual revenue USD 0, actual EPS USD -0.6823

CEL-SCI released FY2025 Q4 earnings on December 29 (EST), actual revenue USD 0, actual EPS USD -0.8612

CEL-SCI released FY2025 Annual Earnings on December 29 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -6.2654 (forecast USD -4.51)

CEL-SCI released FY2025 9 Months earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -6.9454

CEL-SCI released FY2025 Q3 earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -1.3647

CEL-SCI Completes $5.7 Million Market Offering

CEL-SCI Partners with Saudi Pharma Firm to Advance Multikine

CEL-SCI Announces $5.7 Million Market Stock Offering

CEL-SCI Files for Up to $100 Million Shelf Offering

FDA Paves Accelerated Approval Path for CEL-SCI's Multikine Immunotherapy

CEL-SCI Announces Public Offering To Raise $5 Million

CEL-SCI's Multikine Drug Awaits Breakthrough Designation

CEL-SCI released FY2025 Semi-Annual Earnings on May 14 (EST), with actual revenue of USD 0 and EPS of USD -5.4713

CEL-SCI released FY2025 Q2 earnings on May 14 (EST) with actual revenue of USD 0 and EPS of USD -2.3325

CEL-SCI Corporation Seeks Early Approval for Multikine in Head and Neck Cancer Treatment

CEL-SCI Corporation Reports MULTIKINE Treatment Improves Quality of Life for Head and Neck Cancer Patients by 95%

CEL-SCI released FY2025 Q1 earnings on February 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -3.2482

CEL-SCI released FY2024 Annual Earnings on January 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -15.3094 (forecast USD -17.7017)

CEL-SCI released FY2024 Q4 earnings on January 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.9685 (forecast USD -3.3003)

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Silexion Therapeutics

Micware

GCL Global

MetaVia

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Bristol-Myers Squibb Company

CEL-SCI fell 10.47%; AbbVie rose 2.16%, with a transaction volume of USD 668 million; Regeneron Pharmaceuticals rose 0.13%, with a transaction volume of USD 579 million; Amgen rose 2.14%, with a transaction volume of USD 439 million; Gilead Sciences rose 1.18%, with a market capitalization of USD 162.9 billion

Price Alert

Abbvie

Regeneron Pharma

Amgen

Gilead Sciences

U.S. stock market update: CEL-SCI's stock price fell by 10.47%, and insider trading confidence failed to boost market sentiment

CEL-SCI pre-market up 7.38%; Sunshine Biopharma pre-market up 551.18%; GeoVax Labs pre-market up 165.85%; FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026) pre-market up 109.36%

Sunshine Biopharma

GeoVax Labs

Pre-market hot trades in US stocks: Cel-Sci up 7.38% in pre-market, can management's buyback and progress in cancer immunotherapy offset financial weakness?

Cel-Sci has formed a strategic partnership with Amarox for the commercialization of its cancer immunotherapy, Multikine, in Saudi Arabia, with potential expansion to the Gulf Cooperation Council region. This partnership aims to enhance regulatory affairs and marketing efforts. However, Spark's analysis rates CVM stock as Neutral due to weak financial performance and a strong downtrend in technicals. Cel-Sci focuses on developing immunotherapy treatments for cancer, particularly Multikine for head and neck cancer, targeting international markets through partnerships.

Tip Ranks

Cel-Sci Forms Multikine Commercialization Partnership in Middle East

CEL-SCI has raised $7.2 million through a placement agency agreement with ThinkEquity, selling 6 million shares at $1.20 each. The offering closed on May 13, 2026, with a 7% cash fee to the agent and up to $150,000 for expenses. The funds will be used to advance Multikine and for general corporate purposes. There are 30-day issuance restrictions and 45-day lock-ups for directors and officers.

TradingView

CEL-SCI Raises $7.2 Million in Stock Offering; Placement Agreement With ThinkEquity

CEL-SCI Announces Closing of Public Offering | CVM Stock News

StockTitan

CEL-SCI Announces Closing of Public Offering | CVM Stock News

SMTI

ATYR

ERNA

USBC

In Tuesday's intraday session, Ernexa Therapeutics (NASDAQ:ERNA) saw a significant gain of 79.4%, reaching $12.94, while USBC (AMEX:USBC) rose by 55.72% to $0.79. Other notable gainers included Sanara MedTech (NASDAQ:SMTI) up 30.21%, and PACS Group (NYSE:PACS) up 26.47%. Conversely, Tyr Pharma (NASDAQ:ATYR) experienced a decline of 27.4%, followed by CEL-SCI (AMEX:CVM) down 25.89%. The Q1 earnings reports for several companies were released yesterday, impacting stock movements.

benzinga_article

Sanara Medtech

ATYR Pharma

Ernexa Therapeutics

PACS

SPDR S&P Biotech

iShares Global Healthcare

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

iShares Biotechnology ETF

Direxion S&P Biotech Bear 3X

First Trust NYSE Arca Biotech Index Fd

iShares US Healthcare Providers

Invesco Biotechnology & Genome ETF

SPDR S&P Health

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

VG Health

Invesco Nasdaq Biotechnology ETF

Alpha Compute

Macrogenics

WORK Medical Tech

Akari Therap

CVRx

Harrow

Harrow Health Pref Share HROWM 11.875 12/31/27

Harrow Health Pref Share HROWL 8.625 04/30/26

12 Health Care Stocks Moving In Tuesday's Intraday Session

Cel-Sci shares are trading lower after the company announced an offering of 6 million shares at $1.20 per share.

MGNX

In Tuesday's pre-market session, PACS Group saw a significant gain of 17.6%, reaching $37.5, with a market cap of $5.0 billion. Other notable gainers included Akari Therapeutics (+16.31%), Macrogenics (+16.27%), and USBC (+12.69%). Conversely, WORK Medical Tech experienced a sharp decline of 45.7%, followed by CEL-SCI (-26.25%) and Pomdoctor (-22.69%). Overall, the session highlighted substantial movements in health care stocks, influenced by recent earnings reports.

Pomdoctor

Ark Genomic Revolution ETF

iShares US Pharma

iShares US Medical Devices

SPDR S&P Health Equip

Phio Pharmaceuticals

Dyadic

China Pharma

Organigram

Ensysce Biosciences

Ensysce Biosciences - CW22

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

PRSO

Peraso pre-market down 28.25%; CEL-SCI pre-market down 26.95%; BuzzFeed pre-market up 110.78%; Haoxi Health Tech pre-market up 49.78%; Anbo Education pre-market up 39.79%

Peraso

BuzzFeed

Haoxi Health Tech

Ambow Edu

Pre-market hot trades in US stocks: Peraso pre-market down 28.25%; CEL-SCI pre-market down 26.95%

CEL-SCI(CVM.US)

U.S. stock market update: CEL-SCI's stock price fell by 10.47%, and insider trading confidence failed to boost market sentiment

Pre-market hot trades in US stocks: Cel-Sci up 7.38% in pre-market, can management's buyback and progress in cancer immunotherapy offset financial weakness?

Cel-Sci Forms Multikine Commercialization Partnership in Middle East

CEL-SCI Raises $7.2 Million in Stock Offering; Placement Agreement With ThinkEquity

CEL-SCI Announces Closing of Public Offering | CVM Stock News

12 Health Care Stocks Moving In Tuesday's Intraday Session

Cel-Sci shares are trading lower after the company announced an offering of 6 million shares at $1.20 per share.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Pre-market hot trades in US stocks: Peraso pre-market down 28.25%; CEL-SCI pre-market down 26.95%